Search Results

You are looking at 1 - 10 of 14 items for :

  • malignant paraganglioma x
  • Open access x
Clear All
Open access

WenQi Yuan, WeiQinq Wang, Bin Cui, TingWei Su, Yan Ge, Lei Jiang, WeiWei Zhou, and Guang Ning

malignant disease, 7 were paragangliomas of the abdomen, and the rest of the 27 patients were with benign pheochromocytomas. All of the patients were operated in between 2002 and 2006 and clinically monitored at the Shanghai Clinical Center for Endocrine and

Open access

Tiantian Liu, Taylor C Brown, C Christofer Juhlin, Adam Andreasson, Na Wang, Martin Bäckdahl, James M Healy, Manju L Prasad, Reju Korah, Tobias Carling, Dawei Xu, and Catharina Larsson

/76 1/19 (5%) 1/95 (1%) Paraganglioma (PGL) 1/13 (8%) – 1/13 (8%)  Malignant PGL a 1/9 (11%) – 1/9 (11%)  Benign PGL 0/4 – 0/4 a According to the AFIP criteria ( Lack 2007 ). TERT mRNA expression in tumors with C228T Given that

Open access

Diana E Benn, Bruce G Robinson, and Roderick J Clifton-Bligh

:10.1038/ng1095-144 ). Brouwers FM Eisenhofer G Tao JJ Kant JA Adams KT Linehan WM Pacak K 2006 High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic

Open access

Nimrod B Kiss, Andreas Muth, Adam Andreasson, C Christofer Juhlin, Janos Geli, Martin Bäckdahl, Anders Höög, Bo Wängberg, Ola Nilsson, Håkan Ahlman, and Catharina Larsson

extended tumor panel of pheochromocytomas and paragangliomas. Notably and as our previous findings indicated a presence of CIMP in strong association with malignant paragangliomas with SDHB mutation ( Geli et al . 2008 , Kiss et al . 2008 ), the

Open access

Ruth T Casey, Benjamin G Challis, Alison Marker, Deborah Pitfield, Heok K Cheow, Ashley Shaw, Soo-Mi Park, Helen L Simpson, and Eamonn R Maher

Dear Editor, We have read with great interest the recent article by Tufton and coworkers reporting on the risk of metastasis in patients with paraganglioma (PGL) tumours associated with germline SDHA mutations ( Tufton et al . 2017 ). Herein

Open access

J Crona, F Beuschlein, K Pacak, and B Skogseid

dacarbazine treatment improves survival in patients with metastatic and unresectable malignant pheochromocytomas/paragangliomas . Hormones and Cancer 8 108 – 118 . ( https://doi.org/10.1007/s12672-017-0284-7 ) 10.1007/s12672-017-0284-7 Assie G Letouze E

Open access

James F Powers, Brent Cochran, James D Baleja, Hadley D Sikes, Andrew D Pattison, Xue Zhang, Inna Lomakin, Annette Shepard-Barry, Karel Pacak, Sun Jin Moon, Troy F Langford, Kassi Taylor Stein, Richard W Tothill, Yingbin Ouyang, and Arthur S Tischler

dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas . Journal of Clinical Endocrinology and Metabolism 92 3822 – 3828 . ( https://doi.org/10.1210/jc.2007-0709 ) Bechmann N Poser I Seifert V

Open access

Ying Ni, Spencer Seballos, Shireen Ganapathi, Danielle Gurin, Benjamin Fletcher, Joanne Ngeow, Rebecca Nagy, Richard T Kloos, Matthew D Ringel, Thomas LaFramboise, and Charis Eng

neurodegenerative disease ( Bourgeron et al . 1995 , Parfait et al . 2000 ). In contrast, germline heterozygous mutations in the genes encoding the SDH subunits result in hereditary pheochromocytoma–paraganglioma syndrome ( Baysal et al . 2000 , Neumann et al

Open access

Felix Haglund, Carl Christofer Juhlin, Taylor Brown, Mehran Ghaderi, Tiantian Liu, Adam Stenman, Andrii Dinets, Manju Prasad, Reju Korah, Dawei Xu, Tobias Carling, and Catharina Larsson

papillary, follicular, and anaplastic carcinomas of the thyroid, adrenocortical carcinomas, and paragangliomas. Interestingly, the mutations were found to be associated with telomerase activation, telomere length, malignant disease, patient age, and adverse

Open access

Martin Ullrich, Josephine Liers, Mirko Peitzsch, Anja Feldmann, Ralf Bergmann, Ulrich Sommer, Susan Richter, Stefan R Bornstein, Michael Bachmann, Graeme Eisenhofer, Christian G Ziegler, and Jens Pietzsch

Jeunemaitre X Gimenez-Roqueplo AP , 2007 Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas . Journal of Clinical Endocrinology and Metabolism 92 3822 – 3828 . ( https://doi.org/10